Thompson Siegel & Walmsley’s Novo Nordisk NVO Stock Holding History

Thompson Siegel & Walmsley’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.26M	Buy	67,962 +1,054	+2%	+$45.3K	0.06%	267
2026 Q1	$2.46M	Buy	66,908 +3,662	+6%	+$174K	0.04%	270
2025 Q4	$3.22M	Sell	63,246 -1,846	-3%	-$94.4K	0.05%	255
2025 Q3	$3.61M	Buy	+65,092	New	+$3.81M	0.06%	249
2020 Q3	–	Sell	-600	Closed	-$20K	–	667
2020 Q2	$20K	Buy	+600	New	+$19.1K	﹤0.01%	517
2017 Q4	–	Sell	-2,576	Closed	-$62K	–	869
2017 Q3	$62K	Hold	2,576	–	–	﹤0.01%	499
2017 Q2	$55K	Buy	+2,576	New	+$52K	﹤0.01%	520
2015 Q2	–	Sell	-106	Closed	-$3K	–	716
2015 Q1	$3K	Buy	+106	New	+$2.44K	﹤0.01%	675
2013 Q3	–	Sell	-310	Closed	-$5K	–	662
2013 Q2	$5K	Buy	+310	New	+$5.16K	﹤0.01%	630

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Thompson Siegel & Walmsley's NVO Position: Q2 2026 in Review

Thompson Siegel & Walmsley increased its Novo Nordisk (NVO) stake by 1.6% in Q2 2026, buying an estimated $45.3K and bringing the position to 67,962 shares worth $3.26M. The position accounts for 0.06% of the portfolio, ranked #267.

Thompson Siegel & Walmsley first reported a position in NVO in Q2 2013 and has held it in 9 quarters since. The position peaked at $3.61M in Q3 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Thompson Siegel & Walmsley held 67,962 shares of Novo Nordisk worth $3.26M as of Q2 2026.
Thompson Siegel & Walmsley bought 1,054 Novo Nordisk shares in Q2 2026, an estimated $45.3K.
Novo Nordisk made up 0.06% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #267 holding.
Thompson Siegel & Walmsley first reported a position in Novo Nordisk in Q2 2013 and has held it in 9 quarters since.
Thompson Siegel & Walmsley's Novo Nordisk position peaked at $3.61M in Q3 2025.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.